- Home
- AIFF vs NRBO Comparison
AIFF vs NRBO Comparison
Compare AIFF & NRBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIFF
- NRBO
- Stock Information
- Founded
- AIFF 2006
- NRBO N/A
- Country
- AIFF Canada
- NRBO United States
- Employees
- AIFF N/A
- NRBO N/A
- Industry
- AIFF
- NRBO Biotechnology: Pharmaceutical Preparations
- Sector
- AIFF
- NRBO Health Care
- Exchange
- AIFF NYSE
- NRBO Nasdaq
- Market Cap
- AIFF 24.9M
- NRBO 27.9M
- IPO Year
- AIFF N/A
- NRBO N/A
- Fundamental
- Price
- AIFF $2.93
- NRBO $2.38
- Analyst Decision
- AIFF
- NRBO Strong Buy
- Analyst Count
- AIFF 0
- NRBO 1
- Target Price
- AIFF N/A
- NRBO $10.00
- AVG Volume (30 Days)
- AIFF 65.7K
- NRBO 36.9K
- Earning Date
- AIFF 11-14-2024
- NRBO 11-07-2024
- Dividend Yield
- AIFF N/A
- NRBO N/A
- EPS Growth
- AIFF N/A
- NRBO N/A
- EPS
- AIFF N/A
- NRBO N/A
- Revenue
- AIFF $74,000.00
- NRBO N/A
- Revenue This Year
- AIFF N/A
- NRBO N/A
- Revenue Next Year
- AIFF N/A
- NRBO N/A
- P/E Ratio
- AIFF N/A
- NRBO N/A
- Revenue Growth
- AIFF N/A
- NRBO N/A
- 52 Week Low
- AIFF $2.74
- NRBO $2.08
- 52 Week High
- AIFF $15.90
- NRBO $6.75
- Technical
- Relative Strength Index (RSI)
- AIFF 42.66
- NRBO 40.83
- Support Level
- AIFF $2.92
- NRBO $2.30
- Resistance Level
- AIFF $3.36
- NRBO $2.50
- Average True Range (ATR)
- AIFF 0.34
- NRBO 0.23
- MACD
- AIFF -0.02
- NRBO -0.01
- Stochastic Oscillator
- AIFF 9.52
- NRBO 24.75
About AIFF FIREFLY NEUROSCIENCE INC
Firefly Neuroscience Inc is an AI company developing innovative neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support better outcomes for people suffering from mental illnesses and cognitive disorders.
About NRBO NeuroBo Pharmaceuticals Inc.
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.